Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 1

3(42.9%)

Phase 2

3(42.9%)

Phase 3

1(14.3%)

7Total

Phase 1(3)

Phase 2(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06237452Phase 3Recruiting

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Role: lead

NCT05370885Phase 2Terminated

VE202 in Patients With Mild-to-Moderate Ulcerative Colitis

Role: lead

NCT04208958Phase 1Completed

Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer

Role: lead

NCT04899115Phase 2Completed

VE303 for Treatment of Hepatic Encephalopathy (HE)

Role: collaborator

NCT03936998Phase 1Unknown

VE416 for Treatment of Food Allergy

Role: collaborator

NCT03788434Phase 2Completed

Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Role: lead

NCT04236778Phase 1Completed

First-in-human Study of VE303 in Healthy Adult Volunteers

Role: lead

All 7 trials loaded